# Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

> **NCT06602193** · PHASE2 · RECRUITING · sponsor: **Denali Therapeutics Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** BIIB122 225 mg
- **OTHER:** BIIB122-Matching Placebo

## Key facts

- **NCT ID:** NCT06602193
- **Lead sponsor:** Denali Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2026-04-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602193, "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06602193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*